Neurorehabilitation News

DENVER — Losmapimod treatment for those with facioscapulohumeral muscular dystrophy led to no serious adverse events across three clinical trials, according to a poster at the American Academy of Neurology annual meeting.

DENVER — A panel of four experts discussed different aspects of the ways brain health and climate change are linked at the American Academy of Neurology annual meeting.

DENVER — Uncontrolled generalized myasthenia negatively affects patients’ mental health, which in turn negatively impacts their physical symptoms, according to a poster presentation at the American Academy of Neurology annual meeting.

A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy volunteers of a novel PDE4 inhibitor being developed to treat those with cognitive impairment associated with schizophrenia.

Wearable accelerometers may be a reliable tool to track disease progression in patients with amyotrophic lateral sclerosis, researchers wrote in The Lancet.

The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive dyskinesia, according to a press release from the manufacturer.

DENVER — Daily treatment with a suspension of gold crystals was linked to improved outcomes at 96 weeks for those with stable relapsing multiple sclerosis, according to a speaker at the American Academy of Neurology annual meeting.

Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau.

DENVER — A combination therapeutic for amyotrophic lateral sclerosis was nonsuperior to placebo over 48 weeks in a phase 3 clinical trial, according to a presenter at the American Academy of Neurology annual meeting.

DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole.